Immutep Scores FDA Orphan Drug Win for Rare Cancer Treatment Efti
Immutep’s efti shows strong tumor shrinkage in rare cancer STS, earning FDA orphan status to speed development and approval.
/ 2 items
Immutep’s efti shows strong tumor shrinkage in rare cancer STS, earning FDA orphan status to speed development and approval.
Immutep’s key Phase 3 trial for its cancer drug efti was stopped early due to poor results. Analysts from Citizens and Baird downgraded the stock.